AIM ImmunoTech Earnings Reports

AIM ImmunoTech reported a net loss of $5.2 million for the third quarter of 2025, an improvement from the $6.2 million net loss in the prior year's quarter. The company's cash and cash equivalents stood at $25.2 million, providing liquidity for ongoing operations and clinical trials, particularly the DURIPANC trial for pancreatic cancer.

AIM ImmunoTech's Q1 2025 results showed a significant reduction in net loss and operating expenses, despite a decline in revenue. The company faces potential delisting from the NYSE American due to non-compliance with stockholders' equity requirements.

AIM ImmunoTech Inc. reported a significant decrease in net loss for the fiscal year ended December 31, 2024, primarily due to reduced general and administrative expenses and research and development costs. The company's total revenues remained relatively stable, primarily from clinical treatment programs. Despite the improved net loss, the company continues to face challenges with a working capital deficit and its stockholders' equity being below NYSE American listing requirements, raising substantial doubt about its ability to continue as a going concern.